You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Cambridge firm’s cholesterol drug OK’d

Treatment is first product from Aegerion

Aegerion Pharmaceuticals said Monday that it has won Food and Drug Administration approval to sell its first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels.

The condition, homozygous familial hypercholesterolemia, or HoFH, is resistant to statins and other medications typically used to bring high cholesterol under ­control.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week